%0 Journal Article %T Immortalization of erythroid progenitors for in vitro large-scale red cell production %+ Université de Picardie Jules Verne (UPJV) %+ CHU Amiens-Picardie %+ AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre) %A Caulier, A. %A Harmand, L. Guyonneau %A Garcon, Loic %Z 28th Congress of the Societe-Francaise-de-Transfusion-Sanguine (SFTS), Bordeaux, FRANCE, SEP 20-22, 2017 %< avec comité de lecture %@ 1246-7820 %J Transfusion Clinique et Biologique %I Elsevier %V 24 %N 3 %P 263-267 %8 2017 %D 2017 %R 10.1016/j.tracli.2017.06.030 %Z Life Sciences [q-bio]Journal articles %X Population ageing and increase in cancer incidence may lead to a decreased availability of red blood cell units. Thus, finding an alternative source of red blood cells is a highly relevant challenge. The possibility to reproduce in vitro the human erythropoiesis opens a new era, particularly since the improvement in the culture systems allows to produce erythrocytes from induced-Pluripotent Stem Cells (iPSCs), or CD34(+) Hematopoietic Stem Cells (HSCs). iPSCs have the advantage of in vitro self-renewal, but lead to poor amplification and maturation defects (high persistence of nucleated erythroid precursors). Erythroid differentiation from HSC allows a far better amplification and adult-like hemoglobin synthesis. But the inability of these progenitors to self-renew in vitro remains a limit in their use as a source of stem cells. A major improvement would consist in immortalizing these erythroid progenitors so that they could expand indefinitively. Inducible transgenesis is the first way to achieve this goal. To date, the best immortalized-cell models involve strong oncogenes induction, such as c-Myc, Bcl-xL, and mostly E6/E7 HPV16 viral oncoproteins. However, the quality of terminal differentiation of erythroid progenitors generated by these,oncogenes is not optimal yet and the long-term stability of such systems is unknown. Moreover, viral transgenesis and inducible expression of oncogenes raise important problems in term of safety, since the enucleation rate is not 100% and no nucleated cells having replicative capacities should be present in the final product. (C) 2017 Elsevier Masson SAS. All rights reserved. %G English %L hal-03605646 %U https://u-picardie.hal.science/hal-03605646 %~ UNIV-PICARDIE %~ APHP %~ U-PICARDIE %~ HEMATIM